Scientific deep-dive

Ozempic Babies: Fertility, Pregnancy & Contraception on GLP-1 — Evidence Review

Ozempic babies reflect weight loss restoring ovulation in PCOS, reduced pill absorption with tirzepatide (not semaglutide), and GI effects. Ozempic and Wegovy need a 2-month washout before planned pregnancy per the FDA label; stop if you conceive.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
12 min read·15 citations

The honest answer: “Ozempic babies” is a real phenomenon driven by three combined effects — (1) weight loss restores ovulation in many PCOS patients (Crosignani 2003); (2) Mounjaro/Zepbound (tirzepatide) can reduce oral contraceptive absorption, and Foundayo (orforglipron) carries a similar label warning, but Ozempic and Wegovy (semaglutide) do NOT, per Kapitza 2015 and Skelley 2024; (3) severe GI side effects can reduce oral medication absorption during titration. Wegovy and Ozempic both require a 2-month washout before planned pregnancy per FDA label Section 8.3.

The TikTok term “Ozempic baby” refers to unplanned pregnancies that happen in patients on a GLP-1 receptor agonist. The viral framing collapses three very different mechanisms into a single story. Two of them are robustly documented in the peer-reviewed literature — weight loss restoring ovulation in anovulatory PCOS[5][7][6] and tirzepatide’s reduction of oral contraceptive absorption[4]. The third — the assumption that Ozempic itself reduces oral contraceptive effectiveness — is mostly anecdotal. The Kapitza 2015 J Clin Pharmacol[3] pharmacokinetic study showed semaglutide does not produce a clinically meaningful change in ethinyl estradiol exposure, which is why the Ozempic and Wegovy FDA labels[1][2] carry no backup-contraception warning while the Mounjaro, Zepbound, and Foundayo labels do. Separately, both Ozempic and Wegovy labels require a 2-month washout before planned pregnancy due to semaglutide’s long half-life and animal reproductive toxicity, while the Zepbound pregnancy label sets no numeric washout at all. This article walks through each mechanism, the emerging registry data on inadvertent pregnancy exposures, breastfeeding considerations, and a practical washout plan for patients trying to conceive.

What is an “Ozempic baby”? The TikTok term explained

Across 2023-2026, social media filled with first-person accounts of unplanned pregnancies while taking a GLP-1 weight-loss injection — the babies born from them collectively dubbed “Ozempic babies.” Typical versions of the story: a patient with PCOS who hadn’t menstruated regularly in years suddenly conceives within months of starting Ozempic, Wegovy, Mounjaro, or Zepbound; a patient who was confident in her oral contraceptive pill becomes pregnant despite no missed doses; a couple who had been pursuing IVF for years conceives spontaneously after one partner loses 30+ pounds. The term “Ozempic baby” became a stand-in for all of these, even though many of the stories involved Mounjaro or Zepbound (tirzepatide), not Ozempic (semaglutide).

The mechanisms behind these stories are real and distinct. Conflating them — and especially blaming the wrong molecule for the wrong mechanism — produces bad contraceptive decisions. Below, each pathway is broken out with its primary-source evidence.

Mechanism 1: weight loss restores PCOS ovulation

Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility in reproductive-age women. The condition is driven by hyperandrogenism, insulin resistance, and chronic anovulation. In patients with both PCOS and overweight or obesity, modest weight loss reliably improves ovulation frequency. The classic Crosignani 2003 Hum Reprod paper[7] followed 33 anovulatory overweight patients with PCOS on a 1,200 kcal/day diet. Weight loss reduced ovarian volume and the number of microfollicles per ovary, and among the 27 patients with irregular or absent periods, 18 resumed regular cycles and 15 ovulated spontaneously. The fertility finding was the headline: 10 spontaneous pregnancies, all in patients who lost at least 5% of their weight.

The guidelines are more cautious than the viral stories. The 2013 Endocrine Society Clinical Practice Guideline on diagnosis and treatment of PCOS[5] named clomiphene as the first-line therapy for infertility and called the role of weight loss in improving PCOS itself uncertain, while recommending lifestyle intervention in overweight and obese patients for its other health benefits. The 2023 International Evidence-based Guideline for the Assessment and Management of PCOS[6] kept the emphasis on healthy lifestyle and on evidence-based medical therapy and cheaper, safer fertility management. None of the current GLP-1 agents is FDA-approved for fertility treatment.

GLP-1 receptor agonists produce substantial weight loss in obese patients with and without diabetes. The mechanism by which this restores ovulation in PCOS is indirect: weight loss reduces hyperinsulinemia, which in turn reduces ovarian androgen production, which lifts the hyperandrogenic suppression of normal hypothalamic-pituitary-ovarian axis function. The Bolek 2026 pilot prospective study[12] in Clin Nutr ESPEN gave semaglutide + metformin to 20 PCOS patients with obesity and prediabetes: mean weight fell from 98.4 to 85.5 kg after 5 months, and 60% became pregnant during follow-up. The Abedi 2026 narrative review[11] in J Clin Med synthesizes the broader GLP-1 RA fertility-restoration literature.

For many of the women in the viral “Ozempic baby” stories, mechanism 1 is the real driver. A PCOS patient with previously anovulatory cycles who loses 15-25% of body weight on a GLP-1 may resume ovulation without being aware of it — and conceive in a window when she assumes she is still anovulatory and therefore not at meaningful pregnancy risk.

Mechanism 2: contraceptive interactions (which GLP-1s, which products)

This is where the most factual confusion lives. The oral-contraceptive interaction concern applies to tirzepatide (Mounjaro for type 2 diabetes, Zepbound for chronic weight management) — not to semaglutide (Ozempic, Wegovy, Rybelsus). Foundayo (orforglipron), an oral GLP-1 pill, also carries a label instruction to switch to a non-oral method or add a barrier method for 30 days after starting and after each dose increase, because its effect on oral contraceptives has not been tested in a clinical trial[15].

The Kapitza 2015 J Clin Pharmacol study[3] is the main study behind the absent oral-contraceptive warning on the Ozempic and Wegovy labels. Forty-three postmenopausal women with type 2 diabetes took ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg once daily for 8 days under two conditions: before semaglutide, and at steady-state subcutaneous semaglutide 1.0 mg weekly. The ethinyl estradiol AUC ratio (semaglutide / semaglutide-free) was 1.11 (90% CI 1.06-1.15), within the standard 0.80-1.25 bioequivalence window, and Cmax met the bioequivalence criterion for both hormones. Levonorgestrel AUC was 20% higher (ratio 1.20, 90% CI 1.15-1.26), directionally opposite to any contraceptive-failure concern — more progestin, not less. The Ozempic label (Section 12.3) reports no clinically relevant interaction with the oral contraceptive at semaglutide 1 mg. The Skelley 2024 review[4] in J Am Pharm Assoc reached the same conclusion across 6 trials: the one tirzepatide study showed a significant drop in oral contraceptive exposure, while the 5 GLP-1 RA studies showed no statistically or clinically significant effect. (Foundayo was approved after that review.)

Magnitude comparison

FDA-mandated backup-contraception duration after initiation and after each dose escalation, per current US Prescribing Information.[1][2][3][4][15]

  • Ozempic — semaglutide0 days
    no backup required per label
  • Wegovy — semaglutide 2.4 mg0 days
    no backup required — same molecule as Ozempic
  • Mounjaro — tirzepatide28 days
    4 weeks after initiation AND after each dose escalation
  • Zepbound — tirzepatide28 days
    4 weeks after initiation AND after each dose escalation
  • Foundayo (orforglipron)30 days
    30 days after initiation AND after each dose escalation
FDA-mandated backup-contraception duration after initiation and after each dose escalation, per current US Prescribing Information.

Detailed coverage of why semaglutide and tirzepatide diverge on this question lives on two sister pages: Ozempic + birth control: why semaglutide has no OC warning and Mounjaro/Zepbound + birth control: the FDA 4-week backup requirement. The short version: tirzepatide is a dual GIP/GLP-1 receptor agonist with a larger acute gastric-emptying delay; semaglutide is GLP-1-only with a smaller effect, and the difference is clinically meaningful for first-pass oral absorption of small molecules like ethinyl estradiol.

Non-oral contraceptives bypass the GI tract entirely and are not affected by any GLP-1: transdermal patches, vaginal rings, depot injections (Depo-Provera), copper or hormonal IUDs, contraceptive implants (Nexplanon), and barrier methods. A patient on Ozempic or Wegovy with an IUD or implant has no contraceptive-pharmacokinetic risk from the GLP-1.

Mechanism 3: GI absorption disruption (vomiting and diarrhea)

All GLP-1 receptor agonists cause GI side effects during dose titration. Nausea is most common; vomiting and diarrhea occur less frequently but are well-documented. If a patient on an oral contraceptive pill vomits within ~2 hours of taking the pill, absorption can be partially or fully lost — the same way it would be lost during gastroenteritis from any other cause. This is not a semaglutide- or tirzepatide-specific pharmacological interaction; it is general missed-pill physiology.

Standard guidance for any vomiting within 2 hours of an oral contraceptive: take another active pill from a backup pack and use a non-hormonal backup method (condoms) for the next 7 days, per the missed-pill instructions in your specific contraceptive’s package insert. If vomiting is severe enough to be a recurring issue during titration, that is also a prompt to call the prescriber about slowing the titration schedule or switching to an antiemetic strategy.

The FDA label: 2-month washout before planned pregnancy

The contraceptive question and the pregnancy question are distinct. Even though Ozempic does not require backup contraception during therapy, both the Ozempic[1] and Wegovy[2] FDA labels recommend discontinuing semaglutide at least 2 months (8 weeks) before a planned pregnancy. The reasoning is pharmacokinetic plus precautionary, not contraceptive:

  • Half-life: semaglutide has a half-life of approximately 1 week. The Ozempic label says semaglutide will be present in the circulation for about 5 weeks after the last dose (the Wegovy label says 5 to 7 weeks at its higher doses). The 2-month margin adds a safety buffer.
  • Animal reproductive toxicity: in pregnant rats given semaglutide during organogenesis, embryofetal deaths, structural abnormalities and growth changes occurred at clinical exposures; rabbits and monkeys showed early pregnancy losses or structural abnormalities. These findings coincided with marked maternal weight loss. Human data remain limited.
  • Indication-specific framing: the weight-management indication (Wegovy, Zepbound) is itself incompatible with pregnancy — intentional weight loss during pregnancy is not recommended for most patients.

Those two semaglutide labels are the only ones that set a pre-conception window. Mounjaro and Zepbound (tirzepatide), Saxenda (liraglutide) and Foundayo (orforglipron) carry no such number — and pregnancy is not a contraindication on any current GLP-1 label. The weight-management labels (Wegovy, Zepbound, Saxenda, Foundayo) say to discontinue the drug when a pregnancy is recognized; the diabetes labels (Ozempic, Mounjaro) say to use it in pregnancy only if the potential benefit justifies the potential risk to the fetus. Either way, if pregnancy is detected on therapy, contact the prescribing clinician promptly.

What we know about inadvertent pregnancy exposures

The aggregate human pregnancy-exposure dataset for GLP-1 receptor agonists has grown substantially in 2025-2026. Three anchor publications:

  • Hviid 2026 Danish nationwide cohort[9] (Hum Reprod Open) linked Danish registries from 2009 to 2023: 756,636 singleton pregnancies, 529 with periconceptional liraglutide or semaglutide exposure. After propensity matching, only preterm birth risk stayed elevated, and only in women using the drugs for diabetes (semaglutide aOR 1.84, 95% CI 1.24-2.71). In women using them for weight management there was no association (semaglutide aOR 0.71, 95% CI 0.30-1.70), which points to the diabetes rather than the drug.
  • Ozbek 2026 systematic review[8] (Diabetes Obes Metab) reviewed 36 studies of GLP-1 and dual GLP-1/GIP exposure across preconception, pregnancy, and lactation. Periconceptional or early-pregnancy exposure was not consistently associated with major congenital malformations in adjusted analyses, fetal growth restriction, stillbirth, or neonatal death.
  • Jin 2026 case report + literature review[10] (J Gynecol Obstet Hum Reprod) added a single case (semaglutide 0.5 mg weekly until about week 7, healthy term delivery) and reviewed the limited published literature.

Across these sources, as of mid-2026, early exposure has not been consistently linked to major congenital malformations. However, the absolute number of exposed pregnancies remains modest by pharmacoepidemiology standards, confidence intervals are wide for rare outcomes, and the label guidance is unchanged: the weight-management labels say to stop the drug when a pregnancy is recognized, the diabetes labels limit use in pregnancy to cases where benefit justifies risk, and on semaglutide specifically the labels set a 2-month pre-conception window. The honest interpretation for a patient who discovers an inadvertent pregnancy on a GLP-1: the early-exposure data so far are reassuring at the population level, but reassuring is not the same as risk-free, and the next step is to contact the prescriber and obstetric provider promptly about stopping or switching the medication.

Breastfeeding: peptide bioavailability + FDA caution

Section 8.2 of the Ozempic label and the Wegovy injection label[1][2] reports no data on semaglutide in human milk and recommends weighing the developmental and health benefits of breastfeeding against the maternal need for semaglutide and any potential adverse effects on the breastfed infant. This is the standard FDA framing when human data is absent. Wegovy tablets are the exception: the label advises against breastfeeding on them, because the absorption enhancer SNAC passes into milk and may build up in infants.

The molecular biology of semaglutide gives reason for cautious-optimism on transfer risk. Semaglutide is a ~4 kilodalton peptide (molecular weight 4113.58 g/mol per the label[1]) — a GLP-1 analog with two amino acid substitutions and a fatty-acid side chain at lysine 26 that drives albumin binding and the long half-life[14]. Large peptides typically transfer minimally into breast milk, and even when present in milk are subject to enzymatic degradation in the infant gastrointestinal tract that limits oral bioavailability to near-zero. The Diab 2024 study[13] in Nutrients tested milk from eight women on subcutaneous semaglutide at 0, 12 and 24 hours after a dose and did not detect semaglutide in any sample; the worst-case relative infant dose was 1.26%, far below the usual 10% threshold. That fits the expected pharmacology.

Despite this, the FDA Section 8.2 caution remains unchanged and the decision to continue or discontinue breastfeeding on a GLP-1 should be made with the prescriber and pediatrician, weighing the clinical importance of the medication, the maternal indication (type 2 diabetes vs weight management), and the alternative options.

Practical: if you are TTC on Ozempic

A workable pre-conception plan for a patient currently on Ozempic or Wegovy who wants to try to conceive:

  1. Discuss timing with the prescriber. The FDA label specifies 2 months pre-conception washout. Some clinicians extend this to 3 months to ensure complete clearance and a clean baseline.
  2. Maintain contraception during washout. Since Ozempic does not affect oral contraceptive pills, the patient’s usual contraceptive remains effective throughout. The washout period is when fertility may rebound (especially in PCOS) — do not stop contraception until actively trying.
  3. Plan for fertility rebound. If the underlying weight problem and any associated PCOS-anovulation drove original infertility, weight loss on the GLP-1 may have restored ovulation. Patients should expect a meaningful probability of conceiving in the first cycle off contraception once trying.
  4. Plan for weight regain. Discontinuation of GLP-1 therapy is followed by partial weight regain in most patients. For some, this is incompatible with the clinical rationale for treatment; the conversation about restarting GLP-1 after delivery and breastfeeding is best had upfront.
  5. If pregnancy is detected during washout or on therapy, contact the prescribing clinician and obstetric provider right away. The Wegovy label says to stop it when used for weight reduction; the Ozempic label limits use in pregnancy to cases where the benefit justifies the risk.

For numerical washout planning across multiple GLP-1 drugs and formulations, use the GLP-1 Washout Calculator — enter the GLP-1, last dose date, and planned conception date and the tool returns the recommended washout interval based on each drug’s half-life and FDA label guidance.

Quick reference: what to do, by scenario

ScenarioWhat the evidence and FDA labels say to do
On Ozempic + oral contraceptive pill, not trying to conceiveNo change. No backup contraception required (Kapitza 2015; Ozempic label 12.3).
On Foundayo + oral contraceptive pillSwitch to a non-oral method OR add a barrier method for 30 days after starting and 30 days after each dose escalation (Foundayo label).
On Wegovy + IUD / implant / patch / ring / DepoNo interaction. No change.
On Mounjaro or Zepbound + oral contraceptive pillSwitch to a non-oral method OR add a barrier method for 4 weeks after starting and 4 weeks after each dose escalation (Mounjaro/Zepbound label).
PCOS, on Ozempic, anovulatory before therapyOvulation may resume with weight loss. Use contraception actively if not trying to conceive. Discuss with prescriber.
Planning to conceive in next 6 monthsDiscontinue Ozempic/Wegovy at least 2 months before stopping contraception (FDA label Section 8.3). Maintain contraception until ready to try.
Pregnancy detected on OzempicContact prescriber + obstetric provider promptly; Wegovy for weight loss is stopped, and Ozempic for diabetes is continued only if benefit justifies risk. Data so far are mostly reassuring; individual counseling warranted.
Postpartum on Ozempic, breastfeedingFDA Section 8.2 caution stands; Diab 2024 did not detect semaglutide in milk from eight women. Decision should be individualized with prescriber + pediatrician.
Severe persistent vomiting on Ozempic + oral pillFollow missed-pill guidance in your contraceptive package insert (general physiology, not semaglutide-specific). Call prescriber re titration.

Frequently Asked Questions

Yes, but the term blurs three distinct mechanisms. Real cases of unplanned pregnancy on a GLP-1 are driven by some combination of: (1) weight loss restoring ovulation in patients with anovulatory PCOS or obesity-related infertility (well-documented since Crosignani 2003, and the 2023 international PCOS guideline keeps the emphasis on healthy lifestyle); (2) reduced oral contraceptive absorption — a label warning on Mounjaro and Zepbound (tirzepatide) and on Foundayo (orforglipron), NOT on Ozempic or Wegovy (semaglutide); (3) severe GI side effects (vomiting, diarrhea) reducing oral medication absorption during titration. The viral TikTok narrative bundles all three.
No. The Ozempic FDA label has no oral-contraceptive warning. The supporting PK study (Kapitza 2015, J Clin Pharmacol, n=43) showed semaglutide does not change ethinyl estradiol exposure to a clinically relevant degree (AUC ratio 1.11, 90% CI 1.06-1.15, within the 0.80-1.25 bioequivalence window; Cmax also within it) and produced only a small 20% AUC increase for levonorgestrel (directionally the opposite of any contraceptive-failure concern). The Wegovy label says the same. The Mounjaro/Zepbound and Foundayo warnings do not transfer.
At least 2 months (8 weeks), per the FDA Ozempic and Wegovy labels Section 8.3. Semaglutide has a half-life of roughly 1 week, and the Ozempic label says it stays in the circulation for about 5 weeks after the last dose; the 2-month margin adds a safety buffer. Those two semaglutide labels are the only GLP-1 labels that set a pre-conception window — Mounjaro, Zepbound, Saxenda and Foundayo do not. The weight-management labels (Wegovy, Zepbound, Saxenda, Foundayo) say to stop the drug when a pregnancy is recognized; the diabetes labels (Ozempic, Mounjaro) say to use it in pregnancy only if the potential benefit justifies the potential risk to the fetus. If pregnancy is detected on therapy, discontinue immediately and contact your prescriber.
Usually not. The Ozempic FDA label (Section 8.1) says it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and the Wegovy label says to discontinue it in pregnant patients using it for weight reduction. The guidance is driven by animal reproductive-toxicity findings and limited human safety data, plus semaglutide's ~1-week half-life, which is why both Ozempic and Wegovy also call for a 2-month washout before a planned pregnancy. If you conceive on therapy, stop the medication and contact your prescriber right away. Emerging data on inadvertent exposures are mostly reassuring: a 2026 systematic review (Ozbek) found early-pregnancy exposure was not consistently linked to major congenital malformations, and a 2026 Danish cohort (Hviid) found higher preterm-birth risk only in women using these drugs for diabetes, not for weight management. The exposure numbers are still modest and the label guidance is unchanged.
The Hviid 2026 Danish nationwide cohort (Hum Reprod Open) analyzed 756,636 pregnancies, 529 with periconceptional liraglutide or semaglutide exposure. After propensity matching, only preterm birth risk was higher, and only in women using the drugs for diabetes (semaglutide aOR 1.84, 95% CI 1.24-2.71), not for weight management (semaglutide aOR 0.71, 95% CI 0.30-1.70). A 2026 systematic review of 36 studies (Ozbek, Diabetes Obes Metab) found periconceptional or early-pregnancy exposure was not consistently associated with major congenital malformations in adjusted analyses — but the absolute exposure numbers remain modest and the FDA pregnancy guidance is unchanged. The case-report literature (Jin 2026) is accumulating individual exposure descriptions.
The Ozempic label and the Wegovy injection label (Section 8.2) report no data on semaglutide in human milk and recommend weighing the developmental and health benefits of breastfeeding against the maternal need for semaglutide. Wegovy tablets are different: the label advises against breastfeeding on them because of the SNAC absorption enhancer. The 2024 Diab et al. study in Nutrients tested milk from eight women on subcutaneous semaglutide and did not detect semaglutide in any sample (worst-case relative infant dose 1.26%), consistent with semaglutide's large peptide structure (~4 kDa, Lau 2015) making oral bioavailability in the infant unlikely. The FDA label has not been updated to reflect this and the formal label caution still stands — discuss with the prescriber.
For many obese PCOS patients with anovulatory cycles, yes. The Crosignani 2003 paper followed 33 anovulatory overweight PCOS patients on a 1,200 kcal/day diet: of the 27 with irregular or absent periods, 15 ovulated spontaneously, and 10 spontaneous pregnancies occurred in patients who lost at least 5% of their weight. The 2023 International Evidence-based PCOS Guideline keeps the emphasis on healthy lifestyle, while the 2013 Endocrine Society guideline named clomiphene as first-line for infertility and called the role of weight loss in PCOS itself uncertain. A 2026 pilot study (Bolek, Clin Nutr ESPEN) of semaglutide + metformin in 20 obese PCOS patients reported significant weight loss, and 60% became pregnant during follow-up. The mechanism: weight loss reduces hyperinsulinemia and hyperandrogenism, both of which suppress ovulation.
Theoretically yes, but this is general missed-pill physiology, not a semaglutide-specific interaction. If you vomit within 2 hours of taking an oral contraceptive pill, follow the missed-pill instructions in your contraceptive's package insert — typically take another pill and use backup contraception for the next 7 days. This applies to any cause of vomiting, including titration-related GLP-1 nausea. Severe persistent vomiting is also a reason to call the prescriber about dose reduction.
Yes — the Weight Loss Rankings GLP-1 Washout Calculator lets you enter the GLP-1 medication, last dose date, and planned conception date and returns the washout interval per the FDA label half-life and the recommended 2-month buffer. It is a planning aid, not medical advice.

Related on Weight Loss Rankings

Further reading

References

  1. 1.Novo Nordisk Inc. OZEMPIC (semaglutide) injection — US Prescribing Information, Section 8.1 Pregnancy, Section 8.2 Lactation, and Section 8.3 Females and Males of Reproductive Potential (2-month pre-pregnancy washout; revised June 2026). FDA Approved Labeling — DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  2. 2.Novo Nordisk Inc. WEGOVY (semaglutide) injection — US Prescribing Information, Section 8.1 Pregnancy, Section 8.2 Lactation, and Section 8.3 Females and Males of Reproductive Potential (2-month pre-pregnancy washout; revised June 2026). FDA Approved Labeling — DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  3. 3.Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol. 2015. PMID: 25475122.
  4. 4.Skelley JW, Swearengin K, York AL. The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception. J Am Pharm Assoc (2003). 2024. PMID: 37940101.
  5. 5.Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013. PMID: 24151290.
  6. 6.Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertil Steril. 2023. PMID: 37589624.
  7. 7.Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod. 2003. PMID: 12923151.
  8. 8.Ozbek L, Shah E, Al-Shiab R, Inal A, et al. Safety of GLP-1 and Dual GLP-1/GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes. Diabetes Obes Metab. 2026. PMID: 41885132.
  9. 9.Hviid KVR, Banasik K, Mortensen LH, Madsbad S, et al. Periconceptional GLP-1 receptor agonist exposure and obstetric outcomes: a Danish nationwide cohort study. Hum Reprod Open. 2026. PMID: 41852577.
  10. 10.Jin YC, Wu YH, Ma XS, Shi W, Wu ML, et al. Semaglutide exposure in early pregnancy and pregnancy outcomes: A case report and review of literature. J Gynecol Obstet Hum Reprod. 2026. PMID: 41654227.
  11. 11.Abedi MM, Patni MM, Shajahan ANB, Dube R, et al. GLP-1 Receptor Agonists, Fertility Restoration, and Reproductive Safety in Women of Reproductive Age: A Narrative Review. J Clin Med. 2026. PMID: 42122936.
  12. 12.Bolek T, Turňová P, Janošova S, Péč MJ, et al. Effect of semaglutide with metformin for weight loss and fertility in polycystic ovary syndrome (PCOS) patients with obesity: A pilot prospective study. Clin Nutr ESPEN. 2026. PMID: 41421448.
  13. 13.Diab H, Fuquay T, Datta P, Bickel U, Thompson J, Krutsch K. Subcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer into Human Milk. Nutrients. 2024. PMID: 39275201.
  14. 14.Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015. PMID: 26308095.
  15. 15.Eli Lilly and Company. FOUNDAYO (orforglipron) tablets: US Prescribing Information, Section 8.3 Females and Males of Reproductive Potential (30-day oral-contraceptive backup). FDA Approved Labeling, DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.